Pharmaceuticals, Biotechnology and Life Sciences
Faron Pharmaceuticals (Faron), the clinical stage biopharmaceutical company, has recruited the first patient in the Japanese Phase III pivotal clinical trial for the…
Nanobiotixa has announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October.
October is Breast Cancer Awareness Month, a worldwide annual campaign involving thousands of organizations, to highlight the importance of breast awareness, education and research.
Ablynx today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 10,050 common shares have been issued by the Company in exchange for EUR47,303 as the result of the exercise of warrants.
(Reuters Health) – Widely used non-steroidal anti-inflammatory drugs (NSAIDs) are associated with an increased risk of heart failure – even in people without a history of cardiac issues, a recent study suggests.
Merck announced that the phase 3 keynote-045 trial investigating the use of Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).
Premaitha Health has issued 940,000 options over ordinary shares under the Company’s unapproved share option scheme to two employees.
Esperite`s business unit The Cell Factory in collaboration with Women`s and Children`s Health Department of the University of Padua and the Padua University Hospital are developing therapies for inflammatory bowel disease (IBD) using extracellular vesicles (EVs).
Transgene, a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, announced the launch and terms of a share capital increase with shareholders’ preferential subscription rights for a total gross amount of circa €48 million, issue premium included (the “Rights Issue”).
Genomic Vision, DNA molecular combing specialist that develops tests for the diagnostics market and tools for the life sciences research market, has presented, at the Annual Meeting of the American Society of Human Genetics, the initial results of the pilot study undertaken with Quest Diagnostics that aims to identify a biomarker to improve genetic counseling for Spinal Muscular Atrophy (SMA) in the African-American population.